iSpecimen Inc. (ISPC) — SEC Filings

Latest SEC filings for iSpecimen Inc. (ISPC), explained in plain English.

Sentiment Overview: 1 bearish, 49 neutral

Recent Filings (50)

• 10-K Filing — 10-K · 2026-04-01T17:00:21-04:00 [neutral] Risk: medium
• S-1/A Filing — S-1/A · 2025-12-19T00:00:00.000Z [neutral]
• 8-K Filing — 8-K · 2025-12-01T00:00:00.000Z [neutral]
• 8-K Filing — 8-K · 2025-11-21T00:00:00.000Z [neutral]
• 10-Q Filing — 10-Q · 2025-11-17T00:00:00.000Z [neutral]
• 8-K Filing — 8-K · 2025-11-07T00:00:00.000Z [neutral]
• 8-K Filing — 8-K · 2025-11-03T00:00:00.000Z [neutral]
• iSpecimen Inc. Files Definitive Proxy Statement — DEF 14A · 2025-10-14T00:00:00.000Z [neutral] Risk: medium
  iSpecimen Inc. filed its definitive proxy statement on October 14, 2025, for its annual meeting of stockholders. The filing, designated as DEF 14A, outlines the
• iSpecimen Inc. Files S-1/A Amendment — S-1/A · 2025-10-06T00:00:00.000Z [neutral] Risk: medium
  iSpecimen Inc. filed an S-1/A amendment on October 6, 2025, for its registration statement. The filing, with registration number 333-289725, is an amendment to
• iSpecimen Inc. Files S-1/A Amendment — S-1/A · 2025-09-08T00:00:00.000Z [neutral] Risk: medium
  iSpecimen Inc. filed an S-1/A amendment on September 8, 2025, for its registration statement. The company, headquartered in Woburn, MA, is involved in commercia
• iSpecimen Inc. Files 8-K: Regulation FD Disclosure & Exhibits — 8-K · 2025-09-04T00:00:00.000Z [neutral] Risk: low
  On September 4, 2025, iSpecimen Inc. filed a Form 8-K to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain sp
• iSpecimen Inc. Files S-1/A Amendment — S-1/A · 2025-08-25T00:00:00.000Z [neutral] Risk: medium
  iSpecimen Inc. filed an S-1/A amendment on August 25, 2025, to its registration statement. The filing, with registration number 333-289725, pertains to the comp
• iSpecimen Inc. Files 8-K: Regulation FD Disclosure & Exhibits — 8-K · 2025-08-21T00:00:00.000Z [neutral] Risk: low
  On August 21, 2025, iSpecimen Inc. filed a Form 8-K to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain spec
• iSpecimen Inc. Files S-1 Registration Statement — S-1 · 2025-08-20T00:00:00.000Z [neutral] Risk: medium
  iSpecimen Inc. filed an S-1 registration statement with the SEC on August 20, 2025. The company, incorporated in Delaware, is in the commercial physical & biolo
• iSpecimen Inc. Files Q2 2025 10-Q Report — 10-Q · 2025-08-14T00:00:00.000Z [neutral] Risk: medium
  iSpecimen Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2025. The company, incorporated in Delaware and headquartered in Woburn, Ma
• iSpecimen Inc. Files 8-K Report — 8-K · 2025-08-07T00:00:00.000Z [neutral] Risk: low
  On August 7, 2025, iSpecimen Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits, with no spe
• iSpecimen Inc. Files 8-K: Material Agreement and Financials — 8-K · 2025-08-05T00:00:00.000Z [neutral] Risk: medium
  On July 31, 2025, iSpecimen Inc. entered into a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements with
• iSpecimen Inc. Files 8-K for Material Agreement — 8-K · 2025-07-25T00:00:00.000Z [neutral] Risk: medium
  On July 23, 2025, iSpecimen Inc. filed an 8-K report detailing a material definitive agreement. The filing also included Regulation FD disclosures and financial
• iSpecimen Inc. Files 8-K with Corporate Updates — 8-K · 2025-07-10T00:00:00.000Z [neutral] Risk: low
  On July 9, 2025, iSpecimen Inc. filed an 8-K report detailing amendments to its Articles of Incorporation or Bylaws and the filing of Financial Statements and E
• iSpecimen Inc. Files S-1/A Amendment — S-1/A · 2025-07-08T00:00:00.000Z [neutral] Risk: medium
  iSpecimen Inc. filed an S-1/A amendment on July 8, 2025, for its registration statement. The filing, with SEC registration number 333-286958, pertains to the co
• iSpecimen Inc. Files S-1/A Amendment — S-1/A · 2025-06-27T00:00:00.000Z [neutral] Risk: medium
  iSpecimen Inc. filed an S-1/A amendment on June 27, 2025, for its registration statement. The company, incorporated in Delaware with its principal executive off
• iSpecimen Inc. Files 8-K: Board and Compensation Updates — 8-K · 2025-06-24T00:00:00.000Z [neutral] Risk: medium
  On June 18, 2025, iSpecimen Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the election o
• iSpecimen Inc. Files S-1/A Amendment — S-1/A · 2025-06-11T00:00:00.000Z [neutral] Risk: medium
  iSpecimen Inc. filed an S-1/A amendment on June 11, 2025, for its registration statement. The filing, with registration number 333-286958, pertains to the compa
• iSpecimen Inc. Faces Delisting Concerns — 8-K · 2025-06-05T00:00:00.000Z [bearish] Risk: high
  iSpecimen Inc. filed an 8-K on June 5, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer of listi
• iSpecimen Inc. Files S-1/A Amendment — S-1/A · 2025-05-23T00:00:00.000Z [neutral] Risk: medium
  iSpecimen Inc. filed an S-1/A amendment on May 23, 2025, for its registration statement. The company, incorporated in Delaware with principal offices in Woburn,
• iSpecimen Inc. Files Q1 2025 10-Q Report — 10-Q · 2025-05-19T00:00:00.000Z [neutral] Risk: medium
  iSpecimen Inc. filed its 10-Q report for the quarterly period ended March 31, 2025. The company, incorporated in Delaware, is based in Woburn, Massachusetts, an
• iSpecimen Inc. Files S-1 Registration Statement — S-1 · 2025-05-02T00:00:00.000Z [neutral] Risk: medium
  iSpecimen Inc. filed an S-1 registration statement on May 2, 2025, for an unspecified offering. The company, incorporated in Delaware with principal offices in
• iSpecimen Inc. Files 2024 Annual Report — 10-K · 2025-04-14T00:00:00.000Z [neutral] Risk: medium
  iSpecimen Inc. filed its 10-K for the fiscal year ended December 31, 2024. The company, incorporated in Delaware and headquartered in Woburn, Massachusetts, ope
• iSpecimen Inc. Appoints BDO USA, LLP as New Auditor — 8-K · 2025-03-11T00:00:00.000Z [neutral] Risk: medium
  On March 7, 2025, iSpecimen Inc. filed an 8-K report to disclose changes in its certifying accountant. The company has appointed BDO USA, LLP as its new indepen
• iSpecimen Inc. Files 8-K Amendment on Officer/Director Changes — 8-K/A · 2025-02-28T00:00:00.000Z [neutral] Risk: medium
  iSpecimen Inc. filed an amendment (No. 1) to its Form 8-K on February 28, 2025, reporting events that occurred on February 19, 2025. The filing pertains to the
• iSpecimen Inc. Reports Board and Executive Changes — 8-K · 2025-02-24T00:00:00.000Z [neutral] Risk: medium
  On February 19, 2025, iSpecimen Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the depart
• iSpecimen Inc. Files 8-K Report — 8-K · 2025-01-16T00:00:00.000Z [neutral] Risk: low
  On January 16, 2025, iSpecimen Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating update
• iSpecimen Inc. Reports Director Changes and Compensation Adjustments — 8-K · 2024-12-30T00:00:00.000Z [neutral] Risk: medium
  On December 27, 2024, iSpecimen Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the depart
• iSpecimen Inc. Appoints New CMO, Elects Director — 8-K · 2024-12-20T00:00:00.000Z [neutral] Risk: low
  On December 13, 2024, iSpecimen Inc. announced the appointment of Dr. Jonathan S. Roth as Chief Medical Officer and the election of Mr. David J. Miller to its B
• iSpecimen Inc. Files 8-K Report — 8-K · 2024-12-13T00:00:00.000Z [neutral] Risk: low
  On December 13, 2024, iSpecimen Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updat
• iSpecimen Appoints New CMO, Elects Director — 8-K · 2024-12-12T00:00:00.000Z [neutral] Risk: low
  On December 9, 2024, iSpecimen Inc. announced the appointment of Dr. Jonathan S. Roth as Chief Medical Officer and the election of Ms. Jennifer L. Jones to its
• iSpecimen Inc. Reports Director Changes and Compensation Adjustments — 8-K · 2024-11-12T00:00:00.000Z [neutral] Risk: medium
  On November 7, 2024, iSpecimen Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates a shift in
• iSpecimen Inc. Files Q3 2024 10-Q Report — 10-Q · 2024-11-07T00:00:00.000Z [neutral] Risk: medium
  iSpecimen Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates. Key financial figures
• iSpecimen Inc. Files 8-K with Material Agreement Details — 8-K · 2024-10-31T00:00:00.000Z [neutral] Risk: medium
  On October 29, 2024, iSpecimen Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosures and financ
• iSpecimen Inc. Files S-1 Registration Statement — S-1 · 2024-10-18T00:00:00.000Z [neutral] Risk: medium
  iSpecimen Inc. filed an S-1 registration statement on October 18, 2024, to register securities under the Securities Act of 1933. The company, incorporated in De
• iSpecimen Inc. Files 8-K Report — 8-K · 2024-10-02T00:00:00.000Z [neutral] Risk: low
  On July 25, 2024, iSpecimen Inc. filed an 8-K report detailing an event under Regulation FD Disclosure and Other Events. The filing does not contain specific fi
• iSpecimen Inc. Files 8-K: New Agreements & Executive Changes — 8-K · 2024-09-25T00:00:00.000Z [neutral] Risk: medium
  On September 19, 2024, iSpecimen Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also announced the depar
• iSpecimen Inc. Files 8-K with Corporate Updates — 8-K · 2024-09-11T00:00:00.000Z [neutral] Risk: medium
  On September 11, 2024, iSpecimen Inc. filed an 8-K report detailing material modifications to the rights of its security holders and amendments to its articles
• iSpecimen Inc. Files 8-K on Financials — 8-K · 2024-08-06T00:00:00.000Z [neutral] Risk: low
  On August 6, 2024, iSpecimen Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statements and
• iSpecimen Inc. Files Q2 2024 10-Q — 10-Q · 2024-08-06T00:00:00.000Z [neutral] Risk: medium
  iSpecimen Inc. filed its 10-Q for the period ending June 30, 2024, reporting on its financial performance. The filing details various financial statement line i
• iSpecimen Inc. Reports Board Changes and Shareholder Votes — 8-K · 2024-07-22T00:00:00.000Z [neutral] Risk: medium
  On July 17, 2024, iSpecimen Inc. announced changes to its board of directors, including the election of new directors and the departure of existing ones. The co
• iSpecimen Inc. Reports Board and Executive Changes — 8-K · 2024-07-08T00:00:00.000Z [neutral] Risk: medium
  On July 5, 2024, iSpecimen Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the departure o
• iSpecimen Inc. Files 8-K: Material Agreements Entered and Terminated — 8-K · 2024-07-03T00:00:00.000Z [neutral] Risk: medium
  On June 28, 2024, iSpecimen Inc. entered into a Material Definitive Agreement and also terminated a Material Definitive Agreement. The company, incorporated in
• iSpecimen Inc. Files Definitive Proxy Statement for 2024 Annual Meeting — DEF 14A · 2024-06-10T00:00:00.000Z [neutral] Risk: medium
  iSpecimen Inc. filed its definitive proxy statement (DEF 14A) on June 10, 2024, for its annual meeting of stockholders scheduled for July 19, 2024. The filing o
• iSpecimen Inc. Closes $1.5M Private Placement — 8-K · 2024-05-17T00:00:00.000Z [neutral] Risk: medium
  On May 16, 2024, iSpecimen Inc. announced the closing of its previously disclosed private placement of common stock. The company raised approximately $1.5 milli